Literature DB >> 31867081

68Ga-PSMA: a One-stop Shop in Radioactive Iodine Refractory Thyroid Cancer?

Thabo Lengana1, Ismaheel O Lawal1, Kgomotso Mokoala1, Mariza Vorster1, Mike M Sathekge1.   

Abstract

We report a case of a 47-year-old female known with metastatic papillary thyroid cancer. Her treatment history included total thyroidectomy and 3 previous radio ablations with a cumulative dose of 950 mCi of 131I. On follow-up, her thyroglobulin levels had demonstrated a rising trend (from 3789.0 to 4240.0 ug/L) despite a 123I whole-body scan demonstrating a reduction in tracer avid lesions. She was suspected of having radio-resistant disease. The patient underwent both 18F-FDG and 68Ga-PSMA PET/CT imaging with both scans demonstrating congruent lesions however with far greater intensity on the 68Ga-PSMA study. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  18F-FDG; 68Ga-PSMA; Radioactive iodine refractory thyroid; Thyroid cancer

Year:  2019        PMID： 31867081      PMCID： PMC6898693          DOI： 10.1007/s13139-019-00621-x

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  11 in total

Review 1.  The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.

Authors:  Edward B Silberstein
Journal:  Semin Nucl Med       Date:  2011-03       Impact factor: 4.446

2.  Refractory thyroid cancer: a paradigm shift in treatment is not far off.

Authors:  David G Pfister; James A Fagin
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

3.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

4.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

Review 5.  Alternative medical treatment for radioiodine-refractory thyroid cancers.

Authors:  Jin Chul Paeng; Keon Wook Kang; Do Joon Park; So Won Oh; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2011-09-17

Review 6.  Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.

Authors:  Yong Joong Kim; Yong-Il Kim
Journal:  Clin Nucl Med       Date:  2018-10       Impact factor: 7.794

7.  Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.

Authors:  Gulin Ucmak Vural; Burcu Esen Akkas; Nur Ercakmak; Sandip Basu; Abass Alavi
Journal:  Clin Nucl Med       Date:  2012-10       Impact factor: 7.794

8.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.

Authors:  U Feine; R Lietzenmayer; J P Hanke; J Held; H Wöhrle; W Müller-Schauenburg
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

9.  PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics.

Authors:  Andrey Bychkov; Usanee Vutrapongwatana; Supatporn Tepmongkol; Somboon Keelawat
Journal:  Sci Rep       Date:  2017-07-12       Impact factor: 4.379

10.  68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients.

Authors:  Mike Sathekge; Thabo Lengana; Moshe Modiselle; Mariza Vorster; JanRijn Zeevaart; Alex Maes; Thomas Ebenhan; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-08       Impact factor: 9.236
View more
  1 in total

Review 1.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.